Impax ships authorized generic version of Zomig

HAYWARD, Calif. — Impax Labs has launched an authorized generic drug for migraine headaches under a partnership with AstraZeneca, Impax said.

Impax said its generics division, Global Pharmaceuticals, began shipping authorized generic zolmitriptan tablets and orally disintegrating tablets in the 2.5 mg and 5 mg strengths. The drug is a version of AstraZeneca's Zomig.

Zomig had sales of about $196 million during the 12-month period that ended in April, according to IMS Health.

Authorized generics are branded drugs marketed under their generic names at a discounted price, usually under a deal between the drug's manufacturer and a third-party company.